Glycemic metrics in Japanese isCGM users – Analysis by diabetes type and therapy

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2024-07-29 DOI:10.1111/jdi.14233

Wataru Ogawa, Tatsuhiko Urakami, Takashi Kadowaki, Kalvin Kao, Laura Brandner, Kenichiro Shimizu, Timothy C. Dunn

{"title":"Glycemic metrics in Japanese isCGM users – Analysis by diabetes type and therapy","authors":"Wataru Ogawa, Tatsuhiko Urakami, Takashi Kadowaki, Kalvin Kao, Laura Brandner, Kenichiro Shimizu, Timothy C. Dunn","doi":"10.1111/jdi.14233","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims/Introduction</h3>\n \n <p>The FreeStyle Libre (FSL) intermittently scanned continuous glucose monitoring (isCGM) system continually measures interstitial glucose levels and provides the data to users in numerical and graphical formats that guide users in their daily diabetes self-management. Although numerous studies have demonstrated the glycemic benefits of FSL in pediatric and adult populations, few studies have characterized FSL use specifically by Japanese adults with type 1 or 2 diabetes. We utilized established CGM metrics to assess glycemic control in a large cohort of Japanese adults with type 1 and 2 diabetes.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A total of 3,463 anonymized FSL users provided categorization into one of four therapy groups of interest: type 1 diabetes (<i>n</i> = 1,768), type 2 diabetes-multiple daily injections (MDI) (<i>n</i> = 612), type 2 diabetes-basal (BOI) (<i>n</i> = 343), and type 2 diabetes-non-insulin (NIT) (<i>n</i> = 740). Established CGM metrics were used to assess glycemic control.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>All study groups showed relatively good glycemic control. Type 1 diabetes users showed the highest glucose variability (SD, 61 mg/dL; and %CV, 40%), above the established target level (%CV ≤ 36%). type 2 diabetes-MDI and type 2 diabetes-BOI users had similar levels of glucose variability (both within target). Type 2 diabetes-NIT users had the highest mean % time in range (TIR) (84.3%) and largest percentage of users that met the target of %TIR > 70% (87.4%). In contrast, type 1 diabetes users had the lowest mean %TIR (62.6%) and the lowest percentage meeting the established %TIR target (30.5%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>By utilizing CGM devices in daily diabetes care, both healthcare professionals and patients can monitor glycemic excursions and gain insights into their historical glucose control patterns.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14233","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims/Introduction

The FreeStyle Libre (FSL) intermittently scanned continuous glucose monitoring (isCGM) system continually measures interstitial glucose levels and provides the data to users in numerical and graphical formats that guide users in their daily diabetes self-management. Although numerous studies have demonstrated the glycemic benefits of FSL in pediatric and adult populations, few studies have characterized FSL use specifically by Japanese adults with type 1 or 2 diabetes. We utilized established CGM metrics to assess glycemic control in a large cohort of Japanese adults with type 1 and 2 diabetes.

Materials and Methods

A total of 3,463 anonymized FSL users provided categorization into one of four therapy groups of interest: type 1 diabetes (n = 1,768), type 2 diabetes-multiple daily injections (MDI) (n = 612), type 2 diabetes-basal (BOI) (n = 343), and type 2 diabetes-non-insulin (NIT) (n = 740). Established CGM metrics were used to assess glycemic control.

Results

All study groups showed relatively good glycemic control. Type 1 diabetes users showed the highest glucose variability (SD, 61 mg/dL; and %CV, 40%), above the established target level (%CV ≤ 36%). type 2 diabetes-MDI and type 2 diabetes-BOI users had similar levels of glucose variability (both within target). Type 2 diabetes-NIT users had the highest mean % time in range (TIR) (84.3%) and largest percentage of users that met the target of %TIR > 70% (87.4%). In contrast, type 1 diabetes users had the lowest mean %TIR (62.6%) and the lowest percentage meeting the established %TIR target (30.5%).

Conclusions

By utilizing CGM devices in daily diabetes care, both healthcare professionals and patients can monitor glycemic excursions and gain insights into their historical glucose control patterns.

Abstract Image

查看原文本刊更多论文

日本 isCGM 用户的血糖指标 - 按糖尿病类型和疗法进行分析。

目的/简介：FreeStyle Libre（FSL）间歇扫描连续血糖监测（isCGM）系统可持续测量血糖间期水平，并以数字和图表形式向用户提供数据，指导用户进行日常糖尿病自我管理。尽管许多研究都证明了 FSL 在儿童和成人群体中的血糖效益，但很少有研究专门描述日本 1 型或 2 型糖尿病成人使用 FSL 的情况。我们利用已有的 CGM 指标评估了一大批日本 1 型和 2 型糖尿病成人患者的血糖控制情况：共有 3,463 名匿名 FSL 用户提供了四个治疗组中的一个治疗组：1 型糖尿病（n = 1,768）、2 型糖尿病-每日多次注射（MDI）（n = 612）、2 型糖尿病-基础（BOI）（n = 343）和 2 型糖尿病-非胰岛素（NIT）（n = 740）。使用既定的 CGM 指标评估血糖控制情况：所有研究组的血糖控制情况都相对较好。1 型糖尿病患者的血糖变异性最高（SD，61 mg/dL；%CV，40%），高于既定目标水平（%CV ≤ 36%）。二型糖尿病-NIT 用户的平均血糖范围内时间百分比（TIR）最高（84.3%），血糖范围内时间百分比大于 70% 的用户百分比最高（87.4%）。相比之下，1 型糖尿病用户的平均 TIR 百分比最低（62.6%），达到既定 TIR 百分比目标的比例也最低（30.5%）：结论：通过在日常糖尿病护理中使用 CGM 设备，医护人员和患者都可以监测血糖偏移，并深入了解他们的历史血糖控制模式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).